Released Mar 7, 2024, before the open
10-K filed Mar 7, 2024, 67 days after period end · 0001785530-24-000012
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$12.00M-$12.00M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,962,000N/M
Operating Cash Flowderived-$4,585,000N/M
Free Cash Flowderived-$4,783,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$12.00M | -$11.93M | -$17.87M | -$7.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR